Want to see SNWV full AI Analyst Report?
SNWV Stock Chart & Stats
$4.66
$0.17(2.87%)
At close: 4:00 PM EDT
$4.66
$0.17(2.87%)
Day’s Range― - ―
52-Week Range$3.92 - $36.42
Previous Close$6.1
Volume111.03K
Average Volume (3M)53.11K
Market Cap
$48.34M
Enterprise Value$97.34M
Total Cash (Recent Filing)$9.38M
Total Debt (Recent Filing)$20.71M
Price to Earnings (P/E)3.4
Beta1.36
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding8,602,309
10 Day Avg. Volume53,021
30 Day Avg. Volume53,107
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)157.84
Price to Sales (P/S)5.80
P/FCF Ratio132.13
Enterprise Value/Market Cap2.01
Enterprise Value/Revenue2.22
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda4.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$51.35M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue GrowthGrowth in consumables and applicator volumes supports a recurring-use revenue base tied to the installed device fleet. This can improve revenue visibility and customer retention over the next several quarters, while reducing reliance on one-time equipment purchases.
Cash GenerationPositive operating and free cash flow indicate that recent earnings are converting into internally generated funds. Sustained cash generation would help SANUWAVE support R&D, fund commercialization, and reduce debt without relying as heavily on external capital.
Improved ProfitabilityThe shift from substantial historical losses to solid profitability demonstrates meaningful operating improvement, while gross margins near 75% show potential economic value in the technology. If maintained, these margins can support reinvestment and strengthen earnings resilience.
Bears Say
Reimbursement UncertaintyPotential reimbursement reductions could weaken provider economics, slow adoption, and pressure treatment volumes across affected wound-care settings. Management’s withdrawal of revenue guidance confirms that this regulatory change creates material uncertainty for planning and earnings durability.
Capital Sales CannibalizationUsed-system availability is directly cannibalizing new equipment purchases, weakening an important capital-sales revenue stream. This may lengthen replacement and expansion cycles, constrain near-term growth, and make the business more dependent on recurring consumables revenue.
Thin Equity And LeverageA small equity base leaves the capital structure sensitive to earnings volatility even after substantial debt reduction. Elevated leverage can limit financial flexibility, increase the consequences of operating setbacks, and constrain the company’s ability to fund growth internally.
Sanuwave Health News
SNWV FAQ
What was Sanuwave Health’s price range in the past 12 months?
Sanuwave Health lowest stock price was $3.92 and its highest was $36.42 in the past 12 months.
What is Sanuwave Health’s market cap?
Sanuwave Health’s market cap is $48.34M.
When is Sanuwave Health’s upcoming earnings report date?
Sanuwave Health’s upcoming earnings report date is Nov 06, 2026 which is in 25 days.
How were Sanuwave Health’s earnings last quarter?
Sanuwave Health released its earnings results on Aug 06, 2026. The company reported -$0.08 earnings per share for the quarter.
Is Sanuwave Health overvalued?
According to Wall Street analysts Sanuwave Health’s price is currently Overvalued.
Does Sanuwave Health pay dividends?
Sanuwave Health does not currently pay dividends.
What is Sanuwave Health’s EPS estimate?
Sanuwave Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanuwave Health have?
Sanuwave Health has 8,602,309 shares outstanding.
What happened to Sanuwave Health’s price movement after its last earnings report?
Sanuwave Health reported an EPS of -$0.08 in its last earnings report. Following the earnings report the stock price went down -2%.
Which hedge fund is a major shareholder of Sanuwave Health?
Currently, no hedge funds are holding shares in SNWV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanuwave Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.55%
12-Months-Change
Fundamentals
Return on Equity
1728.10%
Trailing 12-Months
Asset Growth
10.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sanuwave Health
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. The company was founded on May 6, 2004 and is headquartered in Eden Prairie, MN.
SNWV Company Deck
SNWV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong execution on the recurring applicator/consumables business with record unit volumes, positive adjusted EBITDA and a solid liquidity position, contrasted with severe near-term headwinds in system sales driven by used-system cannibalization and industry disruption from CMS reimbursement changes. Management is responding by diversifying into stickier hospital and other indications and investing in R&D, but it has withdrawn guidance due to regulatory uncertainty. Highlights around recurring revenue growth and balance sheet health are meaningful, but the magnitude of the capital-sales decline, reimbursement risk, and the guidance withdrawal temper near-term outlook.View all SNWV earnings summariesTechnical Analysis
Cerus
―
Senseonics Holdings
―
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Ownership Overview
21.98% Insiders
7.43% Mutual Funds
21.59% Other Institutional Investors
44.42% Public Companies and
Individual Investors